Ocular Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

New Glaucoma Drugs Yield Large, Lasting Reductions in Intraocular Pressure - Drug Discovery & Development



New Glaucoma Drugs Yield Large, Lasting Reductions in Intraocular Pressure 
Drug Discovery & Development
LBN, applied topically, reduces pressure in the eye of patients with open-angle glaucoma or ocular hypertension via two mechanisms, latanoprost-mediated increase in unconventional outflow and nitric oxide-mediated increase in conventional outflow ...

and more » 


Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)



Business Wire (press release)
 
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... 
Business Wire (press release)
Aerie's first product, RhopressaŽ (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA ...
Today Aerie Pharmaceuticals Inc (NASDAQ:AERI) Reported Decrease in Shorted Shares BZ Weekly
Financial Newsletter - Zacks Zacks
Aerie Pharmaceuticals, Inc. - AERI - Stock Price Today - Zacks Zacks

all 49 news articles » 


First in Class Drug for Glaucoma: What Pharmacists Need to Know - ModernMedicine



Weekly Register
 
First in Class Drug for Glaucoma: What Pharmacists Need to Know 
ModernMedicine
For the first time in more than a decade, a new drug class has been introduced for treatment of glaucoma. Netarsudil opthalmic solution (Rhopressa, Aerie Pharmaceuticals, Inc.) is a first-in-class once-daily therapy that presents another option for ...
Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region Business Wire (press release)
Learn Why Flynn James E Purchased Aerie Pharmaceuticals Inc Stake? Frisco Fastball
Aerie Pharmaceuticals, Inc. (AERI) Analysts See $-1.44 EPS BZ Weekly
Zacks  -Zacks 
all 50 news articles » 


Ocular Therapeutix? to Participate in the 2018 Glaucoma 360 Meeting in San Francisco - Business Wire (press release)



Ocular Therapeutix? to Participate in the 2018 Glaucoma 360 Meeting in San Francisco 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...

and more » 


Announces Pricing of Public Offering of Common Stock - Business Wire (press release)



Announces Pricing of Public Offering of Common Stock 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...

and more » 


Financial Survey: Ocular Therapeutix (OCUL) & Atrion (ATRI) - The Lincolnian Online



Financial Survey: Ocular Therapeutix (OCUL) & Atrion (ATRI) 
The Lincolnian Online
Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase ...

and more » 


Announces Closing of Public Offering of Common Stock - Business Wire (press release)



Frisco Fastball
 
Announces Closing of Public Offering of Common Stock 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...
Financial Newsletter - Zacks Zacks

all 28 news articles » 


Mallinckrodt (MNK) Completes Acquisition Of Sucampo Pharmaceuticals (SCMP) - StreetInsider.com



Mallinckrodt (MNK) Completes Acquisition Of Sucampo Pharmaceuticals (SCMP) 
StreetInsider.com
RESCULAŽ (unoprostone isopropyl ophthalmic solution) 0.15%, is indicated for ocular hypertension and open-angle glaucoma, and is marketed in Japan. VTS-270 is in Phase 3 development for Niemann-Pick Type C (NPC), a rare, neurodegenerative, and ...

and more » 


Does SANTEN PHARMACEUTICA (OTCMKTS:SNPHF) Have Gas After Even More Sellers Involved? - BZ Weekly



Does SANTEN PHARMACEUTICA (OTCMKTS:SNPHF) Have Gas After Even More Sellers Involved? 
BZ Weekly
Santen Pharmaceutical Co., Ltd., together with its subsidiaries, researches and develops, produces, and markets prescription ophthalmic pharmaceutical products for the protection and enhancement of eyesight and health primarily in Japan. The company ...

and more » 


Sit Investment Associates Cut Walt Disney Co/The (DIS) Holding; AEQUUS PHARMACEUTICALS COMMON SHARES ... - Herald KS



Week Herald
 
Sit Investment Associates Cut Walt Disney Co/The (DIS) Holding; AEQUUS PHARMACEUTICALS COMMON SHARES ... 
Herald KS
The company has market cap of $19.91 million. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. It currently has negative earnings. The firm markets tacrolimus IR, an immunosuppressant for the treatment ...
Financial Newsletter - Zacks Zacks
Walt Disney Company (the) - DIS - Stock Price Today - Zacks Zacks
Top 10 Hedge Funds Holding DIS - Slide 1 of 10 - Holdings Channel Holdings Channel

all 91 news articles »